FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy

Vera Therapeutics, Inc.

• FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
• Approval announced on July 7, 2026; this is a significant regulatory milestone for Vera Therapeutics.
• The accelerated approval is based on reduction of proteinuria as a surrogate endpoint.